Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:APTNYSE:CATXNASDAQ:INGNNASDAQ:TLSI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTAlpha Pro Tech$4.65+1.4%$4.51$4.06▼$6.44$50.56M0.328,262 shs2,059 shsCATXPerspective Therapeutics$2.71+4.8%$2.24$1.60▼$16.55$200.79M1.11795,957 shs313,197 shsINGNInogen$6.53-0.1%$6.82$5.70▼$13.33$175.44M1.63239,417 shs50,170 shsTLSITriSalus Life Sciences$5.50-1.3%$5.43$3.50▼$7.90$177.34M0.543,300 shs14,639 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTAlpha Pro Tech-1.50%+4.32%+4.56%-14.53%-9.82%CATXPerspective Therapeutics+7.50%+4.88%+5.31%-1.15%-83.46%INGNInogen-1.36%+9.56%-10.18%-17.86%-24.07%TLSITriSalus Life Sciences-0.36%+2.39%-2.62%-1.76%-29.49%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPTAlpha Pro TechN/AN/AN/AN/AN/AN/AN/AN/ACATXPerspective Therapeutics3.4288 of 5 stars4.60.00.00.02.52.50.6INGNInogen3.9511 of 5 stars3.03.00.03.92.11.71.3TLSITriSalus Life Sciences2.5739 of 5 stars3.63.00.00.01.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTAlpha Pro Tech 0.00N/AN/AN/ACATXPerspective Therapeutics 3.18Buy$12.50362.11% UpsideINGNInogen 2.00Hold$9.5045.59% UpsideTLSITriSalus Life Sciences 3.22Buy$10.9398.88% UpsideCurrent Analyst Ratings BreakdownLatest APT, TLSI, CATX, and INGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025INGNInogenNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Moderate Buy$12.005/14/2025CATXPerspective TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.005/13/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.005/8/2025INGNInogenStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$10.00 ➝ $7.004/9/2025INGNInogenNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/7/2025CATXPerspective TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $10.003/31/2025CATXPerspective TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/28/2025TLSITriSalus Life SciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/27/2025CATXPerspective TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$16.00 ➝ $15.003/26/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $11.003/19/2025CATXPerspective TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTAlpha Pro Tech$58.18M0.87$0.36 per share12.80$5.29 per share0.88CATXPerspective Therapeutics$1.43M140.41N/AN/A$2.67 per share1.01INGNInogen$339.96M0.52N/AN/A$8.79 per share0.74TLSITriSalus Life Sciences$32.14M5.52N/AN/A($0.98) per share-5.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTAlpha Pro Tech$4.19M$0.3712.58∞N/A6.99%6.70%5.76%N/ACATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%8/11/2025 (Estimated)INGNInogen-$102.45M-$1.15N/AN/AN/A-15.89%-27.38%-16.77%8/5/2025 (Estimated)TLSITriSalus Life Sciences-$59.04M-$1.12N/AN/AN/A-206.24%N/A-236.83%8/13/2025 (Estimated)Latest APT, TLSI, CATX, and INGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025TLSITriSalus Life Sciences-$0.20-$0.33-$0.13-$0.39$9.04 million$9.17 million5/7/2025Q1 2025INGNInogen-$0.52-$0.25+$0.27-$0.25$79.57 million$82.28 million3/27/2025Q4 2024TLSITriSalus Life Sciences-$0.35-$0.35N/A-$0.40$8.12 million$8.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTAlpha Pro TechN/AN/AN/AN/AN/ACATXPerspective TherapeuticsN/AN/AN/AN/AN/AINGNInogenN/AN/AN/AN/AN/ATLSITriSalus Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTAlpha Pro TechN/A19.0011.21CATXPerspective TherapeuticsN/A9.609.60INGNInogenN/A2.662.34TLSITriSalus Life SciencesN/A2.402.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTAlpha Pro Tech22.69%CATXPerspective Therapeutics54.66%INGNInogen89.94%TLSITriSalus Life Sciences2.58%Insider OwnershipCompanyInsider OwnershipAPTAlpha Pro Tech15.00%CATXPerspective Therapeutics3.52%INGNInogen1.46%TLSITriSalus Life Sciences27.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPTAlpha Pro Tech12010.86 million9.46 millionOptionableCATXPerspective Therapeutics7074.23 million65.21 millionOptionableINGNInogen1,03026.89 million23.58 millionOptionableTLSITriSalus Life Sciences10632.27 million20.49 millionNot OptionableAPT, TLSI, CATX, and INGN HeadlinesRecent News About These CompaniesRoth Capital Issues Pessimistic Forecast for TLSI EarningsMay 25, 2025 | marketbeat.comRoth Capital Issues Pessimistic Estimate for TLSI EarningsMay 25, 2025 | americanbankingnews.comCantor Fitzgerald Issues Negative Estimate for TLSI EarningsMay 23, 2025 | marketbeat.comCantor Fitzgerald Has Negative View of TLSI FY2025 EarningsMay 23, 2025 | americanbankingnews.comJodi Devlin Sells 4,764 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) StockMay 22, 2025 | insidertrades.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives $10.93 Average Price Target from AnalystsMay 19, 2025 | americanbankingnews.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Average Rating of "Buy" by BrokeragesMay 16, 2025 | marketbeat.comTriSalus Life Sciences (TLSI) Projected to Post Quarterly Earnings on WednesdayMay 16, 2025 | marketbeat.comTriSalus outlines at least 50% revenue growth for 2025 as new Medicare code expands addressable marketMay 15, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Conference Call TranscriptMay 15, 2025 | seekingalpha.comTriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comTriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 GuidanceMay 15, 2025 | businesswire.comBridgeway Capital Management LLC Purchases 50,000 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI)May 15, 2025 | marketbeat.comTriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference CallMay 12, 2025 | businesswire.comTriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial ResultsApril 30, 2025 | finance.yahoo.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Sees Large Decline in Short InterestApril 29, 2025 | marketbeat.comTriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?April 9, 2025 | zacks.comTriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?April 9, 2025 | zacks.comTriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still RisksMarch 30, 2025 | seekingalpha.comTrisalus outlines 50% revenue growth target for 2025 driven by TriNav expansion and new market penetrationMarch 27, 2025 | msn.comTriSalus Life Sciences’ Q4 Loss Exceeds Projections, Revenue Tops Estimates – Retail Stays PessimisticMarch 27, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongMicrosoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock WinsBy Chris Markoch | May 15, 2025View Microsoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock Wins3 Different Ways to Add Gold to Your PortfolioBy Chris Markoch | May 29, 2025View 3 Different Ways to Add Gold to Your PortfolioAPT, TLSI, CATX, and INGN Company DescriptionsAlpha Pro Tech NYSE:APT$4.65 +0.06 (+1.39%) As of 01:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alpha Pro Tech, Ltd., together with its subsidiaries, develops, manufactures, and markets a range of disposable protective apparel, infection control, and building supply products in the United States and internationally. The company operates through Disposable Protective Apparel and Building Supply segments. The Disposable Protective Apparel segment provides shoe covers, bouffant caps, coveralls, frocks, lab coats, and gowns, hoods, as well as face masks and shields. The Building Supply segment offers construction weatherization products, such as housewrap and housewrap accessories, including window and door flashing, and seam tape, synthetic roof underlayment, and self-adhered roof underlayment, as well as other woven material. The company markets its products under the Alpha Pro Tech brand name, as well as under private labels. Its products are used primarily in cleanrooms; industrial safety manufacturing environments; health care facilities, such as hospitals, laboratories, and dental offices; building and re-roofing sites. The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force. Alpha Pro Tech, Ltd. was founded in 1983 and is headquartered in Markham, Canada.Perspective Therapeutics NYSE:CATX$2.70 +0.13 (+4.84%) As of 01:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Inogen NASDAQ:INGN$6.52 -0.01 (-0.08%) As of 01:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.TriSalus Life Sciences NASDAQ:TLSI$5.50 -0.08 (-1.35%) As of 01:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.